Mission Statement, Vision, & Core Values (2026) of Santen Pharmaceutical Co., Ltd.

Founded in Japan in 1890, Santen Pharmaceutical Co., Ltd. (4536.T) has grown into a global leader in eye health, serving patients, consumers, and medical professionals in over 60 countries and regions and supporting the eye health of approximately 50 million people worldwide; guided by its Core Principle, 'Tenki ni sanyo suru,' and a mission to deliver essential, patient-centered value in the prevention, diagnosis, and treatment of eye diseases, Santen pursues continuous advancement through innovation, integrity, and collaboration to realize its vision of 'Happiness with Vision', creating the best vision experience so more people can lead happy, fulfilling lives

Santen Pharmaceutical Co., Ltd. (4536.T) - Intro

• Founded: 1890 (Japan)
• Global footprint: >60 countries and regions
• People supported annually: ~50 million
• Stock listing: Tokyo Stock Exchange (4536.T)

• Core Principle: 'Tenki ni sanyo suru' - explore the secrets and mechanisms of nature to contribute to people's health.
• Patient-centric approach: prioritize meaningful outcomes and quality of life for patients with ophthalmic diseases.
• Science-driven innovation: leverage ophthalmic expertise and focused R&D to create novel therapies and devices.

• Primary aim: deliver novel and significant value in prevention, diagnosis, and treatment of eye diseases.
• Scope: products and services rooted in ophthalmic expertise, evidence, and patient needs.
• Operational focus: clinical development, regulatory excellence, and partnerships to accelerate access.

• Long-term aspiration: create a future where as many patients as possible can lead happy, fulfilling lives through preserved or restored vision.
• Community and societal impact: reduce vision impairment burden; support aging societies with sight-preserving solutions.
• Global reach: expand access in developed and emerging markets to maximize patient impact.

• Patient First - decisions anchored by patient benefit and safety.
• Integrity & Quality - rigorous standards in development, manufacturing, and post‑market surveillance.
• Collaboration - partnering with academia, clinicians, and industry to accelerate innovation.
• Continuous Learning - investing in ophthalmic science and real-world evidence to refine care pathways.
• Sustainability & Responsibility - balancing commercial growth with social value in eye health.

• Targeted R&D: focus on glaucoma, retina, dry eye, and other ophthalmic conditions with high unmet need.
• Manufacturing and supply: global network designed to support product availability across markets.
• Patient reach metric: supporting ~50 million people annually reflects combined product and service reach.

• Listed entity: 4536.T on the TSE; corporate governance aligned with global pharmaceutical norms.
• Investor relevance: strategic priorities and geographic expansion underpin revenue mix and long-term growth potential.

Santen Pharmaceutical Co., Ltd. (4536.T) - Overview

Santen Pharmaceutical Co., Ltd. (4536.T) centers its corporate identity on a clear mission, a vision that guides long-term strategy, and core values that shape daily operations. The company's declared mission-providing essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases-is executed through patient-centric R&D, global commercialization, and service models built from deep ophthalmology expertise and the patient perspective.

• Mission: Deliver essential value for patients and society in preventing, diagnosing, and treating eye diseases through expertise-driven products and patient-focused services.
• Vision: 'Happiness with Vision' - improve quality of life by preserving and restoring sight at scale.
• Global reach: Operates in more than 60 countries and regions to ensure accessibility of ophthalmic solutions.
• Patient-centricity: Solutions tailored to individual patient needs, from clinical development to post-market support.
• Innovation focus: Continuous development of novel treatments and delivery technologies for glaucoma, retinal disease, corneal disorders, and dry eye.

Strategic priorities flow directly from the mission and vision: accelerate pipeline programs in ophthalmology, expand access in emerging markets, strengthen specialty and hospital channels, and scale digital and service offerings that enhance real-world patient outcomes.

Core values and operational principles supporting the mission and vision are embedded across the organization:

• Patient-first mindset - decisions shaped by patient needs and outcomes.
• Scientific rigor - evidence-driven development and clinical validation.
• Global responsibility - equitable access and collaborations to reach diverse populations.
• Integrity and compliance - ethical conduct across research, manufacturing, and commercial activities.
• Collaboration and diversity - cross-functional and cross-border teamwork to accelerate innovation.

Key mission-driven initiatives and metrics demonstrating Santen's commitments include:

• Pipeline concentration: multiple late-stage programs in glaucoma, retinal disease, and ocular surface disorders, with prioritization of high-unmet-need indications.
• Access programs: expansion of market authorizations and distribution networks to increase availability in low- and middle-income regions.
• R&D productivity: sustained R&D investment (~13% of revenue in FY2023) to transform scientific insights into therapeutic options.
• Patient support: disease education, digital adherence tools, and post-market safety surveillance to improve long-term outcomes.

For a deeper corporate context and history that frames how mission and values evolved into Santen's current strategy, see: Santen Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Santen Pharmaceutical Co., Ltd. (4536.T) - Mission Statement

• Mission focus: Improve quality of life through advanced ophthalmic therapies and devices that restore or preserve vision.
• Core Principle linkage: Draw on nature's mechanisms (Tenki ni sanyo suru) to inspire biologically grounded innovations in eye care.
• Patient-centricity: Prioritize treatments for high-burden conditions (glaucoma, dry eye, retinal diseases, myopia, ptosis) that most affect daily living and happiness.
• Global reach: Deliver solutions across more than 60 countries and regions to maximize impact on global eye health.

• 'Happiness with Vision' - enabling the happiest life for each person by providing the best vision experience.
• Strategic implications: accelerate development of therapies for myopia control and ptosis, expand market access in emerging regions, and optimize patient support services.

• R&D allocation: Significant proportion of R&D dedicated to patient-impactful indications - glaucoma, retinal disease, dry eye, myopia control, and surgical ophthalmology (ptosis solutions).
• Clinical development: Ongoing Phase 2/3 programs and lifecycle management for established ophthalmic products to extend therapeutic reach and improve outcomes.
• Commercial strategy: Expand access via regional partnerships, localized regulatory filings, and reimbursement engagement to reduce barriers to care.
• Digital & services: Invest in patient support platforms, teleophthalmology initiatives, and adherence programs to enhance the "best vision experience."

• Myopia: Develop and commercialize evidence-based myopia control solutions to slow progression and reduce lifetime vision loss risk.
• Ptosis & surgical ophthalmology: Expand surgical adjuncts and non-surgical options to improve functional and cosmetic outcomes.
• Access & affordability: Pricing, reimbursement, and patient-assistance programs to broaden access in lower-income regions.
• Sustainability & society: Integrate ESG efforts that support healthy aging, vision screening programs, and workforce eye health.

Santen Pharmaceutical Co., Ltd. (4536.T) - Vision Statement

• Core Principle - 'Tenki ni sanyo suru': exploring nature's mechanisms to contribute to people's health.
• Guiding Principle - carefully identify essentials, decide appropriate actions, and act swiftly.
• Patient Centricity - prioritizing patient needs in strategy, clinical development, and access programs.
• Integrity and Trust - ethical conduct and transparent relationships with patients, professionals, and partners.
• Continuous Advancement - commitment to R&D, lifecycle innovation, and quality improvement.
• Achieve Together - collaborative internal culture and external partnerships to accelerate impact.

• How Core Values translate into measurable actions:
  • Patient Centricity - patient-reported outcomes embedded in pivotal trials; expanded access initiatives in emerging markets.
  • Integrity and Trust - compliance and pharmacovigilance metrics publicly reported; supplier audits and ethical training completion rates.
  • Continuous Advancement - R&D spend as a percentage of sales targets sustained; number of clinical trials initiated annually.
  • Achieve Together - strategic alliances and licensing deals tracked by contribution to late-stage pipeline and revenue diversification.